These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 7930408)

  • 1. Efficacy of thyrotropin-releasing hormone in the treatment of spinal muscular atrophy.
    Takeuchi Y; Miyanomae Y; Komatsu H; Oomizono Y; Nishimura A; Okano S; Nishiki T; Sawada T
    J Child Neurol; 1994 Jul; 9(3):287-9. PubMed ID: 7930408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral administration of the thyrotropin-releasing hormone (TRH) analogue, taltireline hydrate, in spinal muscular atrophy.
    Kato Z; Okuda M; Okumura Y; Arai T; Teramoto T; Nishimura M; Kaneko H; Kondo N
    J Child Neurol; 2009 Aug; 24(8):1010-2. PubMed ID: 19666885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Established Stem Cell Model of Spinal Muscular Atrophy Is Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone Analog.
    Ohuchi K; Funato M; Kato Z; Seki J; Kawase C; Tamai Y; Ono Y; Nagahara Y; Noda Y; Kameyama T; Ando S; Tsuruma K; Shimazawa M; Hara H; Kaneko H
    Stem Cells Transl Med; 2016 Feb; 5(2):152-63. PubMed ID: 26683872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of thyrotropin-releasing hormone for the treatment of spinal muscular atrophy: a preliminary report.
    Tzeng AC; Cheng J; Fryczynski H; Niranjan V; Stitik T; Sial A; Takeuchi Y; Foye P; DePrince M; Bach JR
    Am J Phys Med Rehabil; 2000; 79(5):435-40. PubMed ID: 10994885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New quantitative method for evaluation of motor functions applicable to spinal muscular atrophy.
    Matsumaru N; Hattori R; Ichinomiya T; Tsukamoto K; Kato Z
    Brain Dev; 2018 Mar; 40(3):172-180. PubMed ID: 29395660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Motor nerve conduction studies on children with spinal muscular atrophy.
    Miyanomae Y; Takeuchi Y; Nishimura A; Kawase S; Hirai K; Ochi M; Sawada T
    Acta Paediatr Jpn; 1996 Dec; 38(6):576-9. PubMed ID: 9002289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug treatment for spinal muscular atrophy types II and III.
    Bosboom W; Vrancken AF; van den Berg LH; Wokke JH; Iannaccone ST
    Cochrane Database Syst Rev; 2009 Jan; (1):CD006282. PubMed ID: 19160275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The gross motor function measure is a valid and sensitive outcome measure for spinal muscular atrophy.
    Nelson L; Owens H; Hynan LS; Iannaccone ST;
    Neuromuscul Disord; 2006 Jun; 16(6):374-80. PubMed ID: 16632361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study.
    Kirschner J; Schorling D; Hauschke D; Rensing-Zimmermann C; Wein U; Grieben U; Schottmann G; Schara U; Konrad K; Müller-Felber W; Thiele S; Wilichowski E; Hobbiebrunken E; Stettner GM; Korinthenberg R
    Neuromuscul Disord; 2014 Feb; 24(2):134-42. PubMed ID: 24300782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular analysis and electromyoneurographic abnormalities in Croatian children with proximal spinal muscular atrophies.
    Barisić N; Sertić J; Billi C; Barić I; Sarnavka V; Babić T; Hrabac P; Begović D; Florentin L; Stavljenić-Rukavina A
    Clin Chem Lab Med; 1998 Aug; 36(8):667-9. PubMed ID: 9806483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical therapy in spinal muscular atrophy: a realistic expectation?
    Jennekens FG
    Clin Neurol Neurosurg; 1992; 94 Suppl():S89-92. PubMed ID: 1320532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synaptic defects in type I spinal muscular atrophy in human development.
    Martínez-Hernández R; Bernal S; Also-Rallo E; Alías L; Barceló MJ; Hereu M; Esquerda JE; Tizzano EF
    J Pathol; 2013 Jan; 229(1):49-61. PubMed ID: 22847626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial).
    Stam M; Wadman RI; Wijngaarde CA; Bartels B; Asselman FL; Otto LAM; Goedee HS; Habets LE; de Groot JF; Schoenmakers MAGC; Cuppen I; van den Berg LH; van der Pol WL
    BMJ Open; 2018 Jul; 8(7):e019932. PubMed ID: 30061431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrophysiological findings in childhood spinal muscular atrophies.
    Hausmanowa-Petrusewicz I
    Rev Neurol (Paris); 1988; 144(11):716-20. PubMed ID: 3231960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome measures in spinal muscular atrophy.
    Montes J; Gordon AM; Pandya S; De Vivo DC; Kaufmann P
    J Child Neurol; 2009 Aug; 24(8):968-78. PubMed ID: 19509409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene deletions in Arab patients with spinal muscular atrophy.
    Haider MZ; Moosa A
    J Child Neurol; 1997 Aug; 12(5):310-3. PubMed ID: 9378898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical study of 83 cases with spinal muscular atrophy in children].
    Li H; Wang HL; Shan CM
    Zhonghua Er Ke Za Zhi; 2004 Oct; 42(10):762-4. PubMed ID: 16221347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [F-wave studies in spinal muscular atrophy].
    Bojakowski J
    Neurol Neurochir Pol; 1989; 23(4-6):317-21. PubMed ID: 2637962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salbutamol tolerability and efficacy in patients with spinal muscular atrophy type II.
    Frongia AL; Natera-de Benito D; Ortez C; Alarcón M; Borrás A; Medina J; Vigo M; Padrós N; Moya O; Armas J; Carrera-García L; Expósito-Escudero J; Cuadras D; Bernal S; Martorell L; Colomer J; Nascimento A
    Neuromuscul Disord; 2019 Jul; 29(7):517-524. PubMed ID: 31201046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evoked potentials in spinal muscular atrophy.
    Cheliout-Heraut F; Barois A; Urtizberea A; Viollet L; Estournet-Mathiaud B
    J Child Neurol; 2003 Jun; 18(6):383-90. PubMed ID: 12886971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.